Biologic Drugs With Established Pharmaceutical Class: PCSK9 Inhibitor
✉ Email this page to a colleague
Biologic Drugs With Established Pharmaceutical Class: PCSK9 Inhibitor
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Amgen, Inc. | REPATHA | evolocumab | Injection | 125522 | 2015-08-27 | ⤷ Start Trial | ⤷ Start Trial |
| Amgen, Inc. | REPATHA | evolocumab | Injection | 125522 | 2015-08-27 | 8,030,457 | ⤷ Start Trial |
| Amgen, Inc. | REPATHA | evolocumab | Injection | 125522 | 2015-08-27 | 8,563,698 | ⤷ Start Trial |
| Amgen, Inc. | REPATHA | evolocumab | Injection | 125522 | 2015-08-27 | 8,829,165 | ⤷ Start Trial |
| Amgen, Inc. | REPATHA | evolocumab | Injection | 125522 | 2015-08-27 | 8,859,741 | ⤷ Start Trial |
| Amgen, Inc. | REPATHA | evolocumab | Injection | 125522 | 2015-08-27 | 8,871,914 | ⤷ Start Trial |
| Amgen, Inc. | REPATHA | evolocumab | Injection | 125522 | 2015-08-27 | 8,883,983 | ⤷ Start Trial |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Patent Expiration |
